NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of
August 15 2022 - 8:00AM
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a
biotechnology company focused on discovering and developing
transformative therapeutics for patients, today announced that
abstracts related to NGM120, an antagonist antibody product
candidate that binds GFRAL and is designed to inhibit GDF15
signaling, have been accepted for presentation at the ESMO Annual
Congress, which will take place September 9 – 13, 2022 at the Paris
Expo Porte de Versailles, Paris, and at the AACR Special
Conference: Pancreatic Cancer, which will take place September 13 –
16, 2022 at the Sheraton Boston Hotel, Boston.
NGM120 is an antagonist antibody that binds glial cell-derived
neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth
differentiation factor 15 (GDF15) signaling. NGM scientists have
made several important discoveries related to GDF15, including
identification of its cognate receptor, GFRAL. GFRAL is expressed
in a specific region of the hindbrain, partially outside the blood
brain barrier, and is believed to initiate signaling through
multiple pathways, including the autonomic nervous system. Evidence
has shown that serum levels of GDF15 are elevated in patients with
several tumor types, including non-small cell lung cancer,
melanoma, pancreatic, prostate, colorectal, gastric, esophageal and
ovarian cancer, and are associated with a worse prognosis in
multiple cancers. For more details on NGM Bio’s oncology portfolio
visit NGM Bio’s website at
https://www.ngmbio.com/discovery-engine/oncology/.
Poster Presentation at ESMO Annual Congress
Abstract title: |
Initial Results of a Cohort of Advanced Prostate Cancer Patients in
a Phase 1a Study of NGM120, a First-in-class Anti-GDNF Family
Receptor Alpha Like (GFRAL) Antibody |
Abstract #: |
2545 |
Location: |
Poster Session 11, Poster Area
Hall 4, September 11th 3:00 – 4:00 pm |
|
|
Short-Talk Presentation at AACR Special Conference:
Pancreatic Cancer
Abstract title: |
Initial Results of a Cohort of Advanced Pancreatic Cancer Patients
in a Phase 1b Study of NGM120, a First-in-Class Anti-GDNF Family
Receptor Alpha Like (GFRAL) Antibody |
Session Title: |
Bench to Bedside: The Science
that Underpins Clinical Trials |
Location: |
Plenary Session 2 – Bench to
Beside: The Science that Underpins Clinical Trials, September
14th 10:30 am – 12:30 pm |
|
|
About NGM Bio
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. The company’s biology-centric drug discovery
approach aims
to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. As explorers on the frontier of
life-changing science, NGM Bio aspires to operate one of the most
productive research and development engines in the
biopharmaceutical industry. All therapeutic candidates in the NGM
Bio pipeline have been generated by its in-house discovery engine,
with a disease-agnostic mindset, always led by biology and
motivated by unmet patient need. Today, the company has seven
programs in clinical development, including four in Phase 2 or
2b studies, across three therapeutic areas:
cancer, retinal diseases and liver and
metabolic diseases. Visit us at www.ngmbio.com for more
information.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as “will,” “believed,” “designed,” “initial,”
“promising,” “aspires,” “aims” and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These statements include those related to: NGM Bio’s product
candidates, including the potential of NGM Bio’s oncology product
candidate, NGM120, in solid tumors, prostate cancer and advanced
pancreatic cancer and beliefs about how GFRAL initiates signaling;
NGM Bio’s aspiration to operate one of the most productive research
and development engines in the biopharmaceutical industry; and
other statements that are not historical fact. Because such
statements deal with future events and are based on NGM Bio’s
current expectations, they are subject to various risks and
uncertainties, and actual results, performance or achievements of
NGM Bio could differ materially from those described in or implied
by the statements in this press release. These forward-looking
statements are subject to risks and uncertainties, including,
without limitation, risks and uncertainties associated with the
costly and time-consuming pharmaceutical product development
process and the uncertainty of clinical success, including risks
related to failure or delays in successfully initiating, enrolling,
reporting data from or completing clinical studies, as well as the
risks that results obtained in clinical trials to date may not be
indicative of results obtained in ongoing or future trials and that
NGM Bio’s product candidates may otherwise not be tolerable and
effective treatments in their planned indications; the ongoing
COVID-19 pandemic, which has adversely affected, and could
materially and adversely affect in the future, NGM Bio’s business
and operations, including NGM Bio’s ability to timely supply,
initiate, enroll and complete its ongoing and future clinical
trials; the time-consuming and uncertain regulatory approval
process; NGM Bio’s reliance on third-party manufacturers for its
product candidates and the risks inherent in manufacturing and
testing pharmaceutical products; the sufficiency of NGM Bio’s cash
resources, including to fund its wholly-owned programs, and NGM
Bio’s need for additional capital; and other risks and
uncertainties affecting NGM Bio and its development programs,
including those discussed in the section titled “Risk Factors” in
NGM Bio’s annual report on Form 10-Q for the quarter ended June 30,
2022 filed with the United States Securities and Exchange
Commission (SEC) on August 4, 2022 and future filings and reports
that NGM Bio makes from time to time with the SEC. Except as
required by law, NGM Bio assumes no obligation to update these
forward-looking statements, or to update the reasons if actual
results differ materially from those anticipated in the
forward-looking statements.
Investor Contact:Brian
Schoelkopfir@ngmbio.com |
Media Contact:media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jul 2024 to Aug 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Aug 2023 to Aug 2024